Results 91 to 100 of about 120,748 (311)
Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
A 10-year-old female patient experienced syncope while swimming, and electrocardiography revealed polymorphic ventricular tachycardia, leading to a diagnosis of catecholaminergic polymorphic ventricular tachycardia.
Keiko Shimamoto, MD, PhD +6 more
doaj +1 more source
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García +17 more
wiley +1 more source
Ventricular tachycardia is a malignant cardiac rhythm which frequently causes hemodynamic collapse if not treated early and aggressively. There are several ways to classify ventricular tachycardia, and it is important that physicians working in critical ...
Anurag Singh
doaj
Background Polymorphic ventricular tachycardia (PMVT) is an unstable and often fatal cardiac tachyarrhythmia. While there are many causes of this rhythm, including electrolyte imbalances, ischemia, and genetic disorders, iatrogenic etiologies are ...
Jessica Mao +6 more
doaj +1 more source
Tolga Aksu,1 Tumer Erdem Guler,1 Ebru Golcuk,2 Kazim Serhan Ozcan,1 Ismail Erden1 1Department of Cardiology, Derince Training and Research Hospital, Kocaeli, Turkey; 2Department of Cardiology, School of Medicine, Koç University, Istanbul, Turkey ...
Aksu T +4 more
core
FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran +10 more
wiley +1 more source
Catecholaminergic Polymorphic Ventricular Tachycardia [PDF]
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a challenging and serious disease with a high incidence of sudden cardiac deaths. Patients with CPVT should not be exposed to physical or emotional exertion that might induce ventricular ...
Refaat, Marwan M. +2 more
core +1 more source
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang +3 more
wiley +1 more source

